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Taming the dynamics in a pharmaceutical by
cocrystallization: investigating the impact of the
coformer by solid-state NMR†
Patrick M. J. Szell, a Józef R. Lewandowski, b Helen Blade, c
Leslie P. Hughes, *c Sten O. Nilsson Lill d and Steven P. Brown *a
Pharmaceuticals in their crystalline state may display a range of dynamics that can affect their
physicochemical properties and chemical stability. With pharmaceutical cocrystals continuing to gain
attention, there is an opportunity to investigate how the dynamics are changing in these new solid forms.
Here, we investigate the dynamics in efavirenz, an anti-HIV drug, and a series of its cocrystals using a
combination of DFT calculations and solid-state magic-angle spinning (MAS) NMR spectroscopy. We show
that the crystalline form of efavirenz has a highly dynamic cyclopropyl group, and displays additional
rocking motion. In contrast, the dynamics in the efavirenz cocrystals appear to be tamed, with the
cyclopropyl group in the (efavirenz)(L-proline) cocrystal being the most constrained, and these constraints
originating from a more favourable crystal packing in the cocrystals.
Pharmaceutical cocrystallization is a recent strategy where
an active pharmaceutical ingredient (API) is crystallized with
one or more coformers.1–3 This approach can provide
control of the physicochemical properties, having been
shown to be highly beneficial, for example, in improving
dissolution rates and mechanical properties.4–7 Interestingly,
cocrystals have also been shown to influence the chemical
stability of an API,8,9 potentially extending their shelf-lives.
In recent years, the field of pharmaceutical cocrystals has
flourished, with several commercial products now being
available or under development.10
Despite the general conception that solids are rigid and
fixed in place, molecules in their crystalline state may display
a range of motions. In the context of this study, we refer to
these motions as dynamics. Dynamics have been shown to be
important for the function of proteins,11–13 materials,14 and
molecular machines,15,16 and can be modified by
intermolecular interactions and the crystal packing.17,18
However, molecular motion may be undesirable in
pharmaceuticals as this has been shown to influence their
chemical and physical stabilities.19–21 In addition, dynamics
can render an API difficult to crystallize, making the
development of a commercially relevant process challenging,
while also complicating the process of structural
characterization due to the added uncertainty inherent with
crystallographic disorder.22 As a result, the ability to control
dynamics may lead to better quality drug products with a
consistent performance and improved manufacturability.
Recent work has shown that dynamics in crystalline solids
can be influenced by manipulating the chemical
environment,23,24 the crystallographic environment,22,25,26 or
by introducing a dynamics catalyst.27 More specifically, the
dynamics present in crystalline pharmaceuticals have
previously been investigated,28–31 showing an impact on the
dynamics for preparing new polymorphs,32 the salt form,33,34
or even pharmaceuticals supported in a matrix.35,36 However,
to the best of our knowledge, there is no systematic
investigation on how the dynamics change in
pharmaceuticals as coformers are introduced into the
structure. With the rise of pharmaceutical cocrystals, insights
on how the dynamics are being modified in these new solid
forms can provide crucial structural understandings on the
next generation of medicines.
The anti-HIV pharmaceutical efavirenz (1) features a
dynamic cyclopropyl group that adopts multiple
crystallographic positions,37 and a trifluoromethyl group
which is known to rotate (see Fig. 1). Having a dynamic
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moiety and several of its cocrystals reported in the
Cambridge Structural Database (CSD),37–40 1 provides an
ideal opportunity to investigate if the dynamics are
changing in the cocrystals. Here, we investigate the
dynamics of the cyclopropyl group in 1 and a series of its
reported cocrystals,37–39 as shown in Fig. 1, using a
combination of DFT calculations and solid-state NMR.
Several polymorphs of 1 have previously been reported,
however only form I is investigated here as it is the most
stable of the polymorphs.37
In this work, information on the dynamics of 1 is obtained
using 13C cross polarisation (CP) and 19F solid-state magic-
angle spinning (MAS) NMR spectroscopy under the theme of
NMR crystallography.41,42 Spin–lattice (T1) relaxation time
measurements are applied to extract the thermodynamic
parameters of the fast ps-ns motion of the cyclopropyl ring,
and is interpreted using the Bloembergen–Purcell–Pound
(BPP) relaxation theory.43,44 These data are summarized in
terms of their correlation times (τ), which characterise the
average rate of the dynamic events, and the activation energy
(Ea), the average energy of a dynamic process occurring on
the NMR timescale. The activation energies were further
investigated using transition state (TS) calculations, potential
energy surface calculations, and an analysis of the interaction
energies in each crystal structure. Overall, the objective of
this work is to investigate the dynamics present in 1 and
whether cocrystallization may be a viable strategy to reduce
undesired dynamics in a pharmaceutical.
Results
i) X-ray diffraction
The crystal structure of 1, reported by Mahapatra et al.,37
features three molecules in the asymmetric unit (Z′ = 3), with
one of the cyclopropyl groups exhibiting crystallographic
disorder over two positions. The nature of the disordered
cyclopropyl group in 1 appears to be dynamic in origin, and
consists of a rotation of 136 ± 35° along the ethynyl axis, with
the error considering the sizes of the atomic displacement
parameters (ADPs) as represented by thermal ellipsoids and
shown in Fig. 2. This corresponds to a rotation whereby the
torsion angle between the cyclopropyl group axis and the
efavirenz axis (θO–C–C–C, see Fig. 1) range from −42 ± 26° to 94
± 24° (see Table S37†). Further, as illustrated in Fig. 1, the
experimental structure reveals a swaying of the entire
cyclopropylethynyl group and a bending of the C–CC–C axis
from linearity, corresponding to a change in θsway and θbend
of 17 ± 15° and 29 ± 30°, respectively (see Tables S38 and
S39†). In addition, there is a rocking motion of the double
ring backbone, which is manifested in the crystal structure as
an elongation of the thermal ellipsoids for most non-
cyclopropyl atoms in 1, as shown in Fig. 2. These dynamics
are investigated further in the cocrystals.
The crystal structures of cocrystals 1a and 1d, reported by
Mahapatra et al.37 and de Melo et al.,38 respectively, do not
have crystallographic disorder but the ADPs of the
cyclopropyl group are distorted. The crystal structures of
Fig. 1 (Top) Diagram of the molecular structures used in this study: (1) efavirenz, (a) cyclohexane-1,4-dione, (b) 4,4′-bipyridine, (c) 1,2-di(pyridin-
4-yl) ethane, (d) (E)-1,2-di(pyridin-4-yl)ethene and (e) L-proline. (Bottom) Molecular structure of 1 illustrating the rotation of the cyclopropyl group
associated with a change in the O–C–C–C torsion angle, θO–C–C–C (red circled atoms), the swaying of the cyclopropyl group associated with a
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cocrystals 1b and 1c, reported by Mahapatra et al.37 and de
Melo et al.,38 respectively, both have dynamic crystallographic
disorder and some distortions in the ADPs of the cyclopropyl
groups. Structure 1e is a cocrystal featuring the zwitterion
form of L-proline, and was reported by Marques et al.39
Structure 1e is not disordered and has been solved from
powder diffraction using isotropic displacement parameters
and constraints on bond lengths and angles. All other
structures apart from 1e have been solved by single crystal
X-ray diffraction, and their ORTEP plots45 can be found in
Fig. S37–S41 of the ESI.† The thermal ellipsoids of all atoms
in the structure, which are a measure of the uncertainty on
the atomic positions arising from the magnitude and
direction of the thermal vibrations of atoms, are significantly
larger for 1 than in the cocrystals. The average volume of the
thermal ellipsoids of the CH2 carbon atoms of the
cyclopropyl groups were calculated at a 50% ellipsoid
probability and, as shown in Table 1, is largest in 1 and
decreases in the cocrystals, suggesting the occurrence of
reduced dynamics of the cyclopropyl group in the cocrystals.
While there are additional cocrystals with 1 reported in the
literature,46,47 we have restricted our investigations to the
structures available in the CSD.40 Selected experimental X-ray
parameters have been summarized in Table 2.
ii) DFT calculations
In this section, different types of DFT calculations are applied
to probe and rationalise the observed dynamics. First, DFT
calculations featuring the periodicity of the crystal lattice
were performed to investigate the origins of the energy
barriers of the cyclopropyl dynamics using CASTEP transition
state calculations. All structures were initially optimized
using CASTEP, giving rise to small differences in θO–C–C–C,
θsway and θbend (see Tables S37–S39 of the ESI†). As structures
1a, 1d, and 1e did not have disordered cyclopropyl groups,
the transition state calculations were limited to structures 1,
1b, and 1c, and were performed by specifying the disordered
positions as the starting and end points to the calculations.
In the case of 1, the calculated motion of the cyclopropyl
group was a ΔθO–C–C–C = 121.2° rotation around the ethynyl
axis, a swaying of the cyclopropyl group (Δθsway = 4.8°), a
bending of the ethynyl group (Δθbend = 10.3°), and a rocking
motion of the double ring backbone, as shown in Fig. 3, with
a calculated energy barrier of 8.8 kJ mol−1. The calculated
motion in 1b and 1c were rotations of ΔθO–C–C–C = 60.5° and
79.5° for the cyclopropyl group along the ethynyl axis,
respectively, a small bending of the ethynyl group (Δθbend of
12.5° for 1b, 10.4° for 1c), some swaying (Δθsway = 2.9° for 1b,
7.9° for 1c), and a slight amount of rocking motion (see Fig.
Fig. 2 Thermal ellipsoid plot of pure 1.45 This figure was generated for
the X-ray diffraction structure CSD# 767883 from Mahapatra et al.37
Table 1 Selected X-ray crystallography parameters, DFT-calculated energy of all through-space interactions involving the selected cyclopropyl group,
and activation energy & correlation times derived from the T1(
13C) NMR relaxation experiments for the cyclopropyl groups in 1 and cocrystals 1a–1e
Sample
X-ray DFT 13C NMR relaxation
AssignmentdThermal ellipsoids volumea (Å3) Interaction energyb (kJ mol−1) Ea
c (kJ mol−1) τ25°C/s
1 2.72 −95.3 12 ± 2 [8.8] (3.1 ± 1.0) × 10−11 Site 1 f,g
−142.3 10 ± 2 (1.3 ± 0.5) × 10−11 Site 2g
−99.4 11 ± 2 (1.1 ± 0.3) × 10−12 Site 3g
1a 1.80 −163.9 8 ± 2 (2.6 ± 0.9) × 10−12 Site 1
−120.4 Site 2
1b 1.09 −149.2 2 ± 1 [2.1] (5.6 ± 1.1) × 10−13 Site 1 f
−142.5 Site 2 f
1c 0.58 −145.8 4 ± 2 [5.3] (1.0 ± 0.4) × 10−12 Site 1
−142.5 Site 2 f
1d 0.40 −149.2 3 ± 1 (6.4 ± 1.0) × 10−13 Site 1
−150.6 Site 2
1e 0.25e −218.3 1 ± 1 (1 ± 2) × 10−13 Site 1
a Average volume of the thermal ellipsoids (calculated at a 50% ellipsoid probability) of the CH2 carbon atoms on the cyclopropyl group.
b Breakdown given in Tables S13–S24.† c DFT-calculated Ea are given in brackets.
d Crystallographic assignments are given in Table S37 of the
ESI.† e Isotropic thermal ellipsoids. f Site is crystallographically disordered. g Obtained from three resolved features at δ(13C): 8.8 ppm, 8.0 ppm,
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S33 and S34 of the ESI†). The calculated energy barriers for
1b and 1c were 2.1 kJ mol−1 and 5.3 kJ mol−1.
Potential energy surfaces (PES) were calculated with
DMol3 using DFT for the rotation of the cyclopropyl group of
the efavirenz molecule, corresponding to systematically
changing the θO–C–C–C torsion angle, and are in close
agreement with the TS results obtained from CASTEP. In all
cases, the calculations were performed using a periodic
model of their respective crystal structure. Intriguingly, as
shown in Fig. 4, the PES calculations reveal a broad energy
well with two minima in 1, 1b, and 1c, supporting the
dynamic crystallographic disorder observed in their X-ray
structures. The barriers are small in samples 1, 1b, and 1c,
and appear to be higher in 1. In the case of 1d, while there is
only one position of the cyclopropyl group in the X-ray
structure, the DFT-calculated energy well is also broad but in
this case there is a single energy minimum with an elevated
rotational energy barrier. The PES for both cyclopropyl sites
in 1b, 1c, and 1d were similar. In contrast, the energy profiles
of 1a and 1e are narrower with higher barriers resulting in
crystal structures constrained in a single cyclopropyl
orientation. As there are two unique cyclopropyl groups in
Table 2 Selected experimental X-ray crystallography parameters of the samples investigated in this work
Sample
Acquisition





1 250 6.56 2.72 Crystal 767883 (AJEYAQ02) Mahapatra et al.37
1a 293 9.43 1.80 Crystal 768815 (QUSREC) Mahapatra et al.37
1b 298 4.73 1.09 Crystal 767759 (QUSQOL) Mahapatra et al.37
1c 120 3.79 0.58 Crystal 909386 (XICRUY) de Melo et al.38
1d 120 7.80 0.40 Crystal 909385 (XICSAF) de Melo et al.38
1e 298 3.59 0.25b Powder 1847168 (HUDRAC) Marques et al.39
a Volume of the anisotropic displacement parameter (ADP) of the CH2 group of the cyclopropyl group on the efavirenz molecule at a 50% probability.
The volume was calculated using the equation: volume ¼ 4
3
π U11·U22·U33ð Þ using Uij converted to units of Å. b Isotropic thermal ellipsoids.
Fig. 3 (a) Starting position (C16A C17A C18A), (b) transition state, and (c) ending position (C16B C17B C18B) of the disordered cyclopropyl group in
1 as determined from CASTEP transition state calculations. The red line denotes the torsion angle (θO–C–C–C), and the magenta line highlights the
bending angle (θbend). (d and e) Overlay of the starting position (green) and ending position (blue) from two viewing angles. Only the disordered
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the crystal structure of 1a (Z′ = 2), the PES has been
computed for both groups. Cyclopropyl site 1 for 1a has a
calculated energy barrier of 33 kJ mol−1 (see Fig. 4), whereas
cyclopropyl site 2 for 1a has a calculated energy barrier of 14
kJ mol−1 (see Fig. S36 of the ESI†). In 1e, additional
constraints on the cyclopropyl ring results in a narrow energy
well with a barrier of 32 kJ mol−1 and 38 kJ mol−1 on the
sides of the minimum. Consequently, a single preferred
cyclopropyl position is observed in 1e, in agreement with the
X-ray crystal structure.
In order to provide greater context for the impact of the
crystallographic environment on the energy barrier, the
calculation was repeated on an isolated molecule of 1, with
the PES shown in Fig. S35 of the ESI.† The calculated
rotational barrier for the cyclopropyl group in an isolated
molecule was 2.6 kJ mol−1, which is in excellent agreement
with the 2.8 kJ mol−1 reported in a previous investigation.37
In the investigation reported here, the higher energy barriers
observed computationally in 1, 1a–1e originate from
constraints arising from through-space interactions involving
neighbouring molecules in the crystal.
DFT calculations (with GAUSSIAN16) were used to
estimate the total energy of the through-space interactions
involving each cyclopropyl group, and is referred to here as
the total interaction energy.48,49 Sample 1 has the least
constraining environment of all samples and the cocrystals
have a higher number of constraining interactions, as shown
in Fig. 5, summarized in Table 1, and fully tabulated in
Tables S13–S24 of the ESI.† For instance, the disordered
cyclopropyl group in 1 (site 1) features five interactions from
neighbouring molecules, with the sum of the interaction
energies being −95.3 kJ mol−1. The sum of the interaction
energies in the cocrystals are progressively higher at −120.4
kJ mol−1 in 1a (site 2), and −149.2 kJ mol−1 in 1d (site 1). In
stark contrast, the cyclopropyl group in 1e interacts primarily
with four adjacent cyclopropyl groups from neighbouring
Fig. 4 DFT-calculated potential energy surface for the rotation of a cyclopropyl group along the ethynyl axis in 1 (site 1), 1b (site 2), 1c (site 2), 1d
(site 2), 1a (site 1), and 1e (site 1). The molecular structures above highlight the θO-C-C-C torsion angle and the cyclopropyl orientations. The
Y-axis reports the relative energy. The torsion angles from the X-ray structure (exp.), DFT-optimized structure (calc.), and DFT-calculated transition
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molecules, as shown in Fig. 5. The sum of all interactions
involving the cyclopropyl group in 1e (site 1), which also
includes two weaker interactions, has a total interaction
energy of −218.3 kJ mol−1. Although 1e has a zwitterion
L-proline molecule in the structure, there are no interactions
involving the cyclopropyl group and the L-proline molecule.
Interestingly, the cyclopropyl groups in all cases interact with
other molecules of 1 rather than the coformer.
iii) Solid-state NMR
Solid-state NMR experiments observing both the 13C and 19F
nucleus were applied to confirm the structural models and to
observe changes in the 13C and 19F chemical shifts (δ(13C),
δ(19F)). There have been previous reports of 13C solid-state
NMR experiments to characterize 1, and the results presented
here are in good agreement.50,51 As shown in Fig. 6i, the 13C
Fig. 5 Depiction of the crystallographic packing around the cyclopropyl group for the three distinct cyclopropyl groups in 1 (above) and one of the
two cyclopropyl groups in 1a (site 2), 1d (site 1), and 1e (site 1). The crystal packing of 1b, 1c, and 1d are similar. A simplified depiction of the packing is
shown, with the triangles representing the cyclopropyl group. The black arrows in 1 highlight the two positions of the disordered groups.
Fig. 6 (i) 13C CPMAS solid-state NMR spectra of 1 and cocrystals 1a to 1e, with a magnified view of the cyclopropyl resonances. (ii) T1(
13C)
relaxation times of the CH2 carbon atoms of the cyclopropyl ring at several temperatures. (iii)
19F one-pulse solid-state MAS NMR spectra of the
CF3 group in 1 and cocrystals 1a to 1e. The dashed lines in (ii) denote the fits to eqn (S5),† and the Y-axis scale is different for the top (1e) and
bottom (1 and 1a to 1d) parts. The asterisks denote spinning sidebands, and the dagger denotes a trace amount of starting material (νL(
1H) = 500
MHz, νMAS = 11 750 Hz). Errors on T1(
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solid-state NMR spectra show clear δ(13C) changes between 1
and cocrystals 1a–1e for the resonances assigned to the CH2
and CH carbons of the cyclopropyl group. For instance, a
δ(13C) difference of 4.4 ppm is observed between structures 1
and 1e for the CH carbon of the cyclopropyl group. The full
13C NMR spectra are reported in Fig. S19–S24† together with
assignments based on GIPAW DFT calculations and
discussed further in the ESI.† The 19F solid-state NMR spectra
provide a secondary indicator for the successful preparation
of the cocrystals, observing δ(19F) changes of up to 3.6 ppm,
for instance, between 1 and 1e. A small amount (∼5%,
denoted by a dagger) of residual 1 has been identified from
the 13C, 19F, and PXRD of 1a. Fortunately, the chemical shifts
in 1a were sufficiently resolved from the starting material not
to affect the T1 measurements.
The T1(
13C) relaxation times provide direct insights into
the dynamics occurring on the ps–ns timescales and have
been measured at several temperatures from 3 °C to 45 °C.
Upon the occurrence of motion with a given amplitude near
the 13C Larmor frequency (ωL = 125.9 MHz in this case), the
T1(
13C) relaxation times are shorter (<30 s), such as in 1 and
1a, and are shortest when the rate of the dynamics (τ−1) is at
the Larmor frequency (τ ≈ 1/νL). In this work, the longer
T1(
13C) relaxation times (>30 s), such as for 1b, 1c, 1d and
1e, are associated with dynamics occurring at a rate faster
than the 13C Larmor frequency (τ ≪ 1/ωL). Being the inverse
of the rate, we assume the correlation time at a given
temperature (τx°C) follows the Arrhenius equation (see eqn
(S2)†) and can be calculated from the preexponential factor,
τ0, and the activation energy, Ea. The Ea is an Arrhenius
parameter that describes the average energy of a dynamic
process occurring in this timescale. Both Ea and τ0 are used
to calculate (see eqn (S3)†) the spectral density function,
J(ωL,τ), which is used to calculate T1(
13C). As a result, fitting
the T1(
13C) relaxation time at several temperatures allows for
both τ0 and Ea to be determined. For protonated carbons,
including the CH2 and CH carbon atoms of the cyclopropyl
group, the 13C–1H dipolar coupling relaxation mechanism
dominates the T1(
13C). Moreover, because samples contain
13C at natural abundance, averaging of the rates due to
proton driven spin diffusion typically observed in the solid
state for 13C labelled systems is not a concern.52
In the case of 1, the T1(
13C) relaxation times of the CH2
atoms of the cyclopropyl group are the shortest of all samples
investigated here, ranging between 0.2 s to 2.0 s.
Furthermore, as shown in Fig. 7, the short T1(
13C) relaxation
times extend to carbon atoms well beyond the cyclopropyl
group, with the ethynyl carbons and even all other
protonated carbon atoms on 1 having T1(
13C) values of less
than 15 seconds, and are orders of magnitude shorter than
in the cocrystals. Additional T1(
13C) plots for the other
resonances of 1 are shown in Fig. S31 and S32 of the ESI.†
The T1(
13C) relaxation times of the CH2 cyclopropyl atoms in
1a are slightly longer than for 1, with values of up to 12.7
seconds. As shown in Fig. 6ii, the T1(
13C) relaxation times of
the CH2 carbons are much longer in cocrystals 1b, 1c, and
1d, with T1(
13C) values of up to 60 seconds. In stark contrast,
the T1(
13C) relaxation times of 1e are on the order of 300
seconds, supporting the occurrence of significant changes to
the dynamics.
For each sample, the T1(
13C) relaxation times of the CH2
carbon atoms of the cyclopropyl group have been fitted using
eqn (S5) from the ESI† assuming the presence of a single
dominant motional mode, with the resulting fits shown on
Fig. 6ii. The fitting parameters have been tabulated in Table 1,
summarizing the activation energy (Ea) and the correlation time
at 25 °C (τ25°C). These parameters were verified by fitting the
T1(
13C) relaxation times of the CH carbon atom of the
cyclopropyl group, with all parameters being in excellent
agreement. Using the NMR assignments obtained from the
GIPAW calculations, the thermodynamic parameters have been
assigned to their crystallographic site. The activation energy is
highest in 1 at 12 ± 2 kJ mol−1 and is in close agreement with
the CASTEP transition state calculations. The slightly lower
energy barrier (8.8 kJ mol−1) obtained from these calculations
were likely due to being performed on a reduced model of 1 as
Fig. 7 T1(
13C) for selected carbon atoms in pure 1 as a function of the temperature. The dashed lines in the plots denote the fits for protonated
carbons using eqn (S5)† (see Fig. 6ii and S31 and S32†). The T1(
13C) of the cyclopropylethynyl group were measured from the resonances assigned
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a result of computational limitations. The dynamics in 1 are
assigned to the total motion of the cyclopropyl group observed
from the X-ray crystal structure and DFT calculations, that is,
the rotation of the cyclopropyl group, the swaying of the
cyclopropylethynyl moiety, and the bending of the ethynyl axis
(see Fig. 1). The environment surrounding the disordered
cyclopropyl ring in 1 appears to be loosely packed in the crystal
structure (see Fig. 5), thus providing the required space for the
group to rotate and sway. As shown in Fig. 7 and S31 and S32
of the ESI,† the T1(
13C) for the other protonated carbon atoms
in 1 appear to follow the same thermal activation parameters
as the cyclopropyl group, supporting the occurrence of a
rocking motion of the double ring backbone. The Ea's are
progressively lower in the cocrystals, with 1a having an Ea of 8
± 2 kJ mol−1 & 1e having an Ea of 1 ± 1 kJ mol
−1, and 1b and 1c
are in excellent agreement with the computational results. The
low Ea measured in 1e suggests that due to the heightened
rotational energy barrier originating from the crystal packing,
the cyclopropyl group does not rotate on the time scales to
which T1 measurements are sensitive to, with the experiment
instead capturing local librations of the CH bonds in the
cyclopropyl group. Interestingly, the two CH2 carbons of the
cyclopropyl group in 1e are resolved in the 13C NMR spectrum,
further supporting the absence of chemical exchange by
rotational motion at this timescale. With a decrease in Ea
observed in the cocrystals, the τ25°C of the dynamics in the
cocrystals decreases, and T1(
13C) increases significantly.
Discussion
The experimental X-ray crystal structure shows that the
cyclopropyl groups are highly dynamic in pure 1, which is
reflected by the occurrence of crystallographic disorder and
distorted ADPs. Based on the crystal structure of 1, the
dynamics of the disordered cyclopropyl group have been
assigned to a rotation along the ethynyl axis, a swaying of the
entire cyclopropylethynyl group, a bending of the C–CC–C
axis, and a rocking motion of the double ring backbone. The
dynamics observed in the experimental crystal structure are
also supported by DFT, calculating an energy barrier of 8.8 kJ
mol−1 and reproducing the rocking motion. The DFT-
calculated potential energy surface of 1, as shown in Fig. 4,
shows a relatively low energy barrier between the two
experimentally observed crystallographic positions of the
disordered cyclopropyl group, allowing for the rotation of the
cyclopropyl group to occur. The experimental T1(
13C)
relaxation data supports these observations, with a measured
Ea of 12 ± 2 kJ mol
−1 being in close agreement with the
calculations. The short T1(
13C) across the entire molecule of
1, as shown in Fig. 7, supports the occurrence of rocking
motion, and appears to correlate with the dynamics of the
cyclopropyl groups.
In contrast to 1, there is a remarkable change in the
dynamics occurring in the cocrystals. Given the reduction of
these dynamics, we denote this effect as a taming of the
dynamics. While there was no crystallographic disorder
observed in the X-ray structures of 1a, 1d, and 1e, dynamic
crystallographic disorder with two separated cyclopropyl
positions was observed in the structures of 1b and 1c. The
DFT calculations ascribe the motion in 1b and 1c to a 61°
and 79° rotation of the cyclopropyl group along the ethynyl
axis, respectively, with a smaller amount of rocking motion.
Moreover, the average volumes of the ADPs of the
cyclopropyl's CH2 atoms are significantly smaller in the
cocrystals than in 1, further supporting the occurrence of
tamed dynamics. In 1b and 1c, the PES calculations suggests
the occurrence of a broad double well energy minimum and
low rotational energy barriers, with the cyclopropyl groups
rotating between two positions within this minimum. In 1d,
while the energy minimum is also broad, there is only a
single energy minimum. A significantly higher energy barrier
is observed in 1e, reflecting the presence of additional
interactions constraining the cyclopropyl group.
The taming of the dynamics in 1 is in direct contrast to a
previous investigation showing the potential of catalysing or
promoting dynamics through the introduction of a
halogenated coformer,27,53,54 and can be rationalized by the
crystal packing. As shown in Fig. 5, the crystallographic
environment surrounding the disordered cyclopropyl group
in 1 appears to be loosely packed, allowing the dynamics to
occur with a total calculated interaction energy of −95.3 kJ
mol−1. Of all the samples investigated here, 1e has the most
tightly packed crystallographic environment, as shown in
Fig. 5, and has a total calculated interaction energy of −218.3
kJ mol−1. The interaction energies correlate well with the
experimental results, and are manifested in the PES of 1e as
a narrow energy well with high barriers on both sides of the
minimum, constraining the dynamics of the cyclopropyl
group. Interestingly, the melting point of 1e was 164.1 °C,
which is the highest of all compounds and is 25.2 °C above
that of pure 1, supporting the occurrence of some
stabilization in the cocrystal.
The ability to tame the dynamics in 1 through the
introduction of a coformer, arises from a twofold effect: by
reducing the rotational freedom to a single energy minimum
on the PES, such as in 1a, 1d, and 1e, and by increasing the
energy barrier surrounding this energy minimum, such as in
1e. In order to place these results in a wider context, a search
of the CSD database40 for cyclopropyl groups was conducted
(see section VI of the ESI†). Of the 166 structures that
featured both a cyclopropyl group and disorder, in 37% of
the cases, the disorder involved the cyclopropyl group. With
pharmaceuticals featuring increasingly complex molecules,
the strategy of cocrystallization may be helpful in taming
troublesome dynamics that are known to complicate
crystallization, structural characterization, physicochemical
stability, and commercial manufacturing.
We recognise that the amorphous phase may offer
advantages over the crystalline phase in terms of solubility,
but from the perspective of pharmaceutical development, an
amorphous form may present significant challenges in terms
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mobility has been found to reduce chemical stability in
amorphous pharmaceuticals,21 and 1 in particular has been
shown to have multiple degradation pathways.55 As part of
our investigation, we did attempt to prepare the pure
amorphous form of 1, but it quickly converted to the
crystalline form within hours, precluding our investigation.
Polymer-stabilized amorphous solid dispersions is a potential
route to amorphous pharmaceuticals, and we note that this
approach has been investigated on 1.56–61 However, the cost
of developing and commercialising a polymer-stabilised solid
dispersion can be significant, and alternative strategies to
develop commercially attractive medicines are always sought,
such as cocrystallisation. Interestingly, new cocrystals
featuring 1 have been recently reported, and have been
shown to be stable for 6 months without chemical
degradation.62
In conclusion, we report an instance of taming dynamics
in a pharmaceutical using cocrystallization as a strategy.
While the pure starting material 1 has a highly dynamic
cyclopropyl group and displays an additional rocking motion
of the double ring backbone, X-ray crystallography, DFT
calculations, and solid-state NMR results support that the
cocrystals have remarkably less dynamics. The most
significant changes were observed in the L-proline cocrystal,
1e, where the cyclopropyl group is being constrained in its
position by intermolecular interactions arising from the
crystal packing. This study provides the first systematic
evidence of the ability to tame the dynamics occurring in
pharmaceuticals by cocrystallization, potentially leading




Efavirenz (1, >98%), 1,2-di(pyridin-4-yl)ethane (c, >98%), and
L-proline (e, >99%) were purchased from Tokyo Chemical
Industry. Cyclohexane-1,4-dione (a, 98%), 4,4′-bipyridine (b,
99%) and (E)-1,2-di(pyridin-4-yl)ethene (d, 97%) were
purchased from Sigma Aldrich. HPLC grade acetonitrile was
purchased from VWR. All cocrystals were prepared by
solvent-assisted grinding for 30 minutes using a Retsch
MM400 ball mill in a 5 mL stainless steel milling jar, a single
10 mm stainless steel milling ball, and a milling frequency of
30 Hz. Each cocrystal was prepared at a 300 mg scale with 30
μL of acetonitrile in either a 1 : 1 stoichiometric ratio (1a, 1e)
or 2 : 1 stoichiometric ratio (1b, 1c, 1d) and recovering 90% of
the resulting powder.
13C solid-state NMR
All samples were packed into 4 mm zirconium oxide MAS
rotors, and experiments were performed on a Bruker Avance
III spectrometer operating at a 1H Larmor frequency of 500
MHz using a 4 mm Bruker HFX probe. A magic angle
spinning rate of 11 750 Hz was used throughout all
experiments. The 1D 13C CPMAS spectra were acquired using
a ramped contact pulse on 1H (from 50% to 100%
amplitude),63 a contact time of 2 ms, a 1H π/2 pulse duration
of 2.5 μs, and co-adding 1024 transients. SPINAL64 proton
decoupling64 was used with a 1H nutation frequency of 100
kHz and a 4.4 μs pulse length. The 13C spectrum was
calibrated using glycine and referenced to 176.0 ppm relative
to TMS at 0 ppm.65,66 The T1(
13C) measurements were
performed using the same cross-polarization parameters
followed by an inversion recovery sequence, with a 13C π/2
pulse duration of 4 μs. A total of 8 delays were used for all
inversion recovery experiments, with delays adjusted to
appropriately sample the T1 curve. Temperatures were
calibrated externally using the 207Pb resonance of lead
nitrate.67,68 Additional 19F → 13C CPMAS experiments were
used to measure the T1(
13C) of the trifluoromethyl group.
These experiments were performed using a 4 ms contact time
with a ramped contact pulse,63 SPINAL-64 19F decoupling at a
19F nutation frequency of 62.5 kHz, and a 19F π/2 pulse
duration of 4 μs.
19F solid-state NMR
All samples were packed into 4 mm zirconium oxide MAS
rotors, and experiments were performed on a Bruker Avance
III spectrometer operating at a 1H Larmor frequency of 500
MHz using a 4 mm Bruker HFX probe. A magic angle
spinning rate of 11 750 Hz was used throughout all
experiments. The 1D 19F spectra were acquired using a π/2
pulse with SPINAL64 1H decoupling at a 1H nutation
frequency of 100 kHz and a 4.8 μs pulse length, co-adding 32
transients. An inversion recovery sequence was used to
measure the T1(
19F) relaxation times with 8 variable delays,
collecting 16 transients at each delay. These delays were
manually adjusted to appropriately sample the T1(
19F) curve
of each sample. The 19F chemical shifts were referenced
using PTFE to −122.0 ppm.69
Powder X-ray diffraction
Powder X-ray diffraction experiments were performed on a Bruker
D4 Endeavor diffractometer, scanning 2θ from 2° to 65° with
steps of 0.02° at a rate of 5° per minute (Cu Kα1/2 = 1.5418 Å).
Thermogravimetric analysis
Thermogravimetric analysis was performed on a TA
Instrument Q2000, heating the sample in an Al pan from 25
°C to 300 °C at a constant heating rate of 10 °C min−1.
NMR calculations
All DFT70–72 calculations were performed using the gauge-
including projector augmented-wave (GIPAW)73 method as
implemented in CASTEP74 as part of Materials Studio version
17.75 The structural model used in the calculations used the
structures published on the CSD: 767883 (1),37 768815 (1a),37
767759 (1b),37 909386 (1c),38 909385 (1d),38 1847168 (1e).39
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beginning with a geometry optimization routine with
constrained unit cell parameters prior to calculating the
NMR chemical shifts. The geometry optimization was
performed with TS DFT-D correction,77 on the fly ultrasoft
pseudopotentials, and Koelling–Harmon relativistic
treatment. The cut-off energies and k-point separations can
be found in Table S1 of the ESI.† NMR calculations were
subsequently performed using the same parameters as the
geometry optimization, apart from the cut-off energy. The
calculated σcalc values were extracted using a script and
converted into δcalc using a σref(
13C) of 170 ppm and the
equation δcalc = σref – σcalc. The σiso(
19F) were averaged
between the three fluorine atoms on the same CF3 group.
The σref(
19F) values are given in the figure captions.
Transition state calculations
The transition state search calculations were performed using
CASTEP, OFG ultrasoft pseudopotentials, TS DFT-D, and the
linear synchronous transit method.78,79 A k-point separation
of 0.05 Å−1 and a cut-off energy of 700 eV was used in the
calculation, optimizing the transition state. The calculations
were performed on 1, 1b, and 1c by specifying the disordered
positions as the starting and end points, with the calculation
finding the transition state between both conformations. The
transition state calculation for the cyclopropyl rotation in
pure 1 was performed by removing distant molecules from
the unit cell in order to reduce computational costs.
Potential energy surface calculations
Potential energy surface (PES) calculations were performed
using DMol3 (ref. 80 and 81) as part of Materials Studio,
using the crystal structures as models and featuring
periodicity. The torsion angle between the cyclopropyl group
and the main efavirenz molecular fragment (θO–C–C–C) was
modified at steps of 10°, optimizing the structure at each
step with a constraint on the torsion angles. The calculations
were performed using the DNP basis set, the GGA PBE
functional,76 TS DFT-D corrections,77 and a k-point
separation of 0.05 Å−1.
Crystal interactions analysis
Crystal Interaction (CrysIn), a tool developed in-house, was
used to evaluate the static interactions between molecules
present in a crystal based on DFT.48 The intermolecular
interaction energies in the first coordination cell of each
molecule in the asymmetric unit of the crystal were
calculated using B3LYP-D3/6-31G(d,p) as reported in
GAUSSIAN16.49 This is a comparable method to that
employed in, for instance, the energy framework
calculations in Crystal Explorer82 or PIXEL.83 This approach
enables the quantification of the intermolecular interactions
present in a crystal.84,85
Author contributions
PMJS conceived and designed the experiments, prepared and
analyzed the samples, performed the data analysis and
computational work, and prepared the manuscript. JRL, HB,
LPH, SONL, and SPB designed the experiments, performed
the data analysis, prepared the manuscript, supervised the
work, and provided guidance.
Conflicts of interest
The authors declare no conflicts of interest.
Acknowledgements
This work was funded by Innovate UK and AstraZeneca (grant
number: KTP11570). The authors thank Lydia Coates from
AstraZeneca for performing the thermogravimetric analysis.
Data for this study are provided as a supporting data set from
WRAP, the Warwick Research Archive Portal at https://wrap.
warwick.ac.uk/157143/.
References
1 D. J. Berry and J. W. Steed, Adv. Drug Delivery Rev., 2017, 117,
3–24.
2 G. R. Desiraju, J. Am. Chem. Soc., 2013, 135, 9952–9967.
3 P. Brázda, L. Palatinus and M. Babor, Science, 2019, 364,
667–669.
4 O. Almarsson and M. J. Zaworotko, Chem. Commun.,
2004, 1889–1896.
5 N. K. Duggirala, M. L. Perry, O. Almarsson and M. J.
Zaworotko, Chem. Commun., 2016, 52, 640–655.
6 G. Bolla and A. Nangia, Chem. Commun., 2016, 52,
8342–8360.
7 J. F. Remenar, S. L. Morissette, M. L. Peterson, B. Moulton,
J. M. MacPhee, H. R. Guzmán and O. Almarsson, J. Am.
Chem. Soc., 2003, 125, 8456–8457.
8 Y. Gao, J. Gao, Z. Liu, H. Kan, H. Zu, W. Sun, J. Zhang and S.
Qian, Int. J. Pharm., 2012, 438, 327–335.
9 Y. Gao, H. Zu and J. Zhang, J. Pharm. Pharmacol., 2011, 63,
483–490.
10 R. Shaikh, R. Singh, G. M. Walker and D. M. Croker, Trends
Pharmacol. Sci., 2018, 39, 1033–1048.
11 J. R. Lewandowski, M. E. Halse, M. Blackledge and L.
Emsley, Science, 2015, 348, 578–581.
12 J. A. Davey, A. M. Damry, N. K. Goto and R. A. Chica, Nat.
Chem. Biol., 2017, 13, 1280–1285.
13 S. Kosol, A. Gallo, D. Griffiths, T. R. Valentic, J. Masschelein,
M. Jenner, E. L. C. de Los Santos, L. Manzi, P. K. Sydor, D.
Rea, S. Zhou, V. Fülöp, N. J. Oldham, S. C. Tsai, G. L. Challis
and J. R. Lewandowski, Nat. Chem., 2019, 11, 913–923.
14 P. K. Biswas, S. Saha, T. Paululat and M. Schmittel, J. Am.
Chem. Soc., 2018, 140, 9038–9041.
15 S. Kassem, A. T. L. Lee, D. A. Leigh, V. Marcos, L. I. Palmer



























































































CrystEngCommThis journal is © The Royal Society of Chemistry 2021
16 G. De Bo, M. A. Y. Gall, S. Kuschel, J. De Winter, P. Gerbaux
and D. A. Leigh, Nat. Nanotechnol., 2018, 13, 381–385.
17 J. M. Lamley, C. Öster, R. A. Stevens and J. R. Lewandowski,
Angew. Chem., Int. Ed., 2015, 54, 15374–15378.
18 V. Kurauskas, S. A. Izmailov, O. N. Rogacheva, A. Hessel, I.
Ayala, J. Woodhouse, A. Shilova, Y. Xue, T. Yuwen, N.
Coquelle, J. P. Colletier, N. R. Skrynnikov and P. Schanda,
Nat. Commun., 2017, 8, 145.
19 K. Grzybowska, M. Paluch, A. Grzybowski, Z. Wojnarowska,
L. Hawelek, K. Kolodziejczyk and K. L. Ngai, J. Phys. Chem.
B, 2010, 114, 12792–12801.
20 E. Shalaev, K. Wu, S. Shamblin, J. F. Krzyzaniak and
M. Descamps, Adv. Drug Delivery Rev., 2016, 100,
194–211.
21 S. Yoshioka and Y. Aso, J. Pharm. Sci., 2007, 96, 960–981.
22 P. M. J. Szell, S. P. Brown, L. P. Hughes, H. Blade and S. O.
Nilsson Lill, Chem. Commun., 2020, 56, 14039–14042.
23 J. Baudry, J. Am. Chem. Soc., 2006, 128, 11088–11093.
24 S. Khazaei and D. Sebastiani, J. Chem. Phys., 2016, 145,
234506.
25 X. Wang, P. A. Beckmann, C. W. Mallory, A. L. Rheingold,
A. G. DiPasquale, P. J. Carroll and F. B. Mallory, J. Org.
Chem., 2011, 76, 5170–5176.
26 X. Wang, F. B. Mallory, C. W. Mallory, H. R. Odhner and
P. A. Beckmann, J. Chem. Phys., 2014, 140, 194304.
27 P. M. J. Szell, S. Zablotny and D. L. Bryce, Nat. Commun.,
2019, 10, 916.
28 H. E. Kerr, L. K. Softley, K. Suresh, A. Nangia, P. Hodgkinson
and I. R. Evans, CrystEngComm, 2015, 17, 6707–6715.
29 A. Pajzderska, K. Drużbicki, M. A. Gonzalez, J. Jenczyk, B.
Peplińska, M. Jarek, J. Mielcarek and J. Wąsicki, J. Phys.
Chem. B, 2014, 118, 6670–6679.
30 D. C. Apperley, A. F. Markwell, I. Frantsuzov, A. J. Ilott, R. K.
Harris and P. Hodgkinson, Phys. Chem. Chem. Phys.,
2013, 15, 6422–6430.
31 X. Kong, L. A. O'Dell, V. Terskikh, E. Ye, R. Wang and G. Wu,
J. Am. Chem. Soc., 2012, 134, 14609–14617.
32 R. K. Chandrappa, P. Ochsenbein, C. Martineau, M.
Bonin, G. Althoff, F. Engelke, H. Malandrini, B. Castro,
M. El Hajji and F. Taulelle, Cryst. Growth Des., 2013, 13,
4678–4687.
33 E. Carignani, S. Borsacchi and M. Geppi, J. Phys. Chem. A,
2011, 115, 8783–8790.
34 S. O. Nilsson Lill, C. M. Widdifield, A. Pettersen, A. Svensk
Ankarberg, M. Lindkvist, P. Aldred, S. Gracin, N. Shankland,
K. Shankland, S. Schantz and L. Emsley, Mol. Pharmaceutics,
2018, 15, 1476–1487.
35 E. Carignani, S. Borsacchi, P. Blasi, A. Schoubben and M.
Geppi, Mol. Pharmaceutics, 2019, 16, 2569–2578.
36 A. Pajzderska, K. Drużbicki, P. Bilski, J. Jenczyk, M. Jarek, J.
Mielcarek and J. Wąsicki, J. Phys. Chem. C, 2019, 123,
18364–18375.
37 S. Mahapatra, T. S. Thakur, S. Joseph, S. Varughese and G. R.
Desiraju, Cryst. Growth Des., 2010, 10, 3191–3202.
38 A. C. C. de Melo, I. F. de Amorim, M. d. L. Cirqueira and
F. T. Martins, Cryst. Growth Des., 2013, 13, 1558–1569.
39 M. Marques, W. Braga, J. S. Junior, L. Prado, H. Rocha, F.
Ferreira, G. Ferreira and J. A. L. C. Resende, CSD
Communication, 2019.
40 C. R. Groom, I. J. Bruno, M. P. Lightfoot and S. C. Ward,
Acta Crystallogr., Sect. B: Struct. Sci., Cryst. Eng. Mater.,
2016, 72, 171–179.
41 R. K. Harris, Solid State Sci., 2004, 6, 1025–1037.
42 B. Elena, G. Pintacuda, N. Mifsud and L. Emsley, J. Am.
Chem. Soc., 2006, 128, 9555–9560.
43 D. A. Torchia and A. Szabo, J. Magn. Reson., 1982, 49,
107–121.
44 N. Bloembergen, E. M. Purcell and R. V. Pound, Phys. Rev.,
1948, 73, 679–712.
45 L. J. Farrugia, J. Appl. Crystallogr., 2012, 45, 849–854.
46 R. Chadha, A. Saini, P. Arora, S. Chanda and
Dharamvirsinghjain, Int. J. Pharm. Pharm. Sci., 2012, 4,
244–250.
47 J. B. Ngilirabanga, P. P. Rosa, M. Aucamp, Y. Kippie and H.
Samsodien, J. Drug Delivery Sci. Technol., 2020, 60, 101958.
48 A. Halme, M. J. Quayle, S. O. Nilsson Lill, A. Pettersen, M.
Fransson and C. Boissier, Cryst. Growth Des., 2019, 19,
3670–3680.
49 M. J. Frisch, G. W. Trucks, H. B. Schlegel, G. E. Scuseria,
M. A. Robb, J. R. Cheeseman, G. Scalmani, V. Barone, G. A.
Petersson, H. Nakatsuji, X. Li, M. Caricato, A. V. Marenich, J.
Bloino, B. G. Janesko, R. Gomperts, B. Mennucci, H. P.
Hratchian, J. V. Ortiz, A. F. Izmaylov, J. L. Sonnenberg,
F. Ding Williams, F. Lipparini, F. Egidi, J. Goings, B. Peng, A.
Petrone, T. Henderson, D. Ranasinghe, V. G. Zakrzewski, J.
Gao, N. Rega, G. Zheng, W. Liang, M. Hada, M. Ehara, K.
Toyota, R. Fukuda, J. Hasegawa, M. Ishida, T. Nakajima, Y.
Honda, O. Kitao, H. Nakai, T. Vreven, K. Throssell, J. A.
Montgomery Jr., J. E. Peralta, F. Ogliaro, M. J. Bearpark, J. J.
Heyd, E. N. Brothers, K. N. Kudin, V. N. Staroverov, T. A.
Keith, R. Kobayashi, J. Normand, K. Raghavachari, A. P.
Rendell, J. C. Burant, S. S. Iyengar, J. Tomasi, M. Cossi, J. M.
Millam, M. Klene, C. Adamo, R. Cammi, J. W. Ochterski,
R. L. Martin, K. Morokuma, O. Farkas, J. B. Foresman and
D. J. Fox, Gaussian 16 Rev. C.01, Wallingford, CT, 2016.
50 E. G. R. Sousa, E. M. de Carvalho, R. A. da Silva San Gil,
T. C. D. Santos, L. B. Borré, O. A. Santos-Filho and J. Ellena,
J. Pharm. Sci., 2016, 105, 2656–2664.
51 C. Fandaruff, G. S. Rauber, A. M. Araya-Sibaja, R. N. Pereira,
C. E. M. de Campos, H. V. A. Rocha, G. A. Monti, T.
Malaspina, M. A. S. Silva and S. L. Cuffini, Cryst. Growth
Des., 2014, 14, 4968–4975.
52 J. R. Lewandowski, J. Sein, H. J. Sass, S. Grzesiek, M. Blackledge
and L. Emsley, J. Am. Chem. Soc., 2010, 132, 8252–8254.
53 L. Catalano, S. Pérez-Estrada, G. Terraneo, T. Pilati, G.
Resnati, P. Metrangolo and M. A. Garcia-Garibay, J. Am.
Chem. Soc., 2015, 137, 15386–15389.
54 L. Catalano, S. Perez-Estrada, H. H. Wang, A. J.-L. Ayitou,
S. I. Khan, G. Terraneo, P. Metrangolo, S. Brown and M. A.
Garcia-Garibay, J. Am. Chem. Soc., 2017, 139, 843–848.
55 M. Kurmi, A. Sahu, D. K. Singh, I. P. Singh and S. Singh,



























































































CrystEngComm This journal is © The Royal Society of Chemistry 2021
56 S. Sarabu, V. R. Kallakunta, S. Bandari, A. Batra, V. Bi, T.
Durig, F. Zhang and M. A. Repka, Carbohydr. Polym.,
2020, 233, 115828.
57 A. Schittny, S. Philipp-Bauer, P. Detampel, J. Huwyler and M.
Puchkov, J. Controlled Release, 2020, 320, 214–225.
58 H. C. Arca, L. I. Mosquera-Giraldo, D. Dahal, L. S. Taylor and
K. J. Edgar, Mol. Pharmaceutics, 2017, 14, 3617–3627.
59 Z. M. M. Lavra, D. Pereira de Santana and M. I. Ré, Drug Dev.
Ind. Pharm., 2017, 43, 42–54.
60 J. Pawar, A. Tayade, A. Gangurde, K. Moravkar and P. Amin,
Eur. J. Pharm. Sci., 2016, 88, 37–49.
61 J. Yang, K. Grey and J. Doney, Int. J. Pharm., 2010, 384,
24–31.
62 B. H. Jaswanth Gowda, S. K. Nechipadappu, S. J. Shankar, M.
Chavali, K. Paul, M. G. Ahmed, A. Sanjana and H. K.
Shanthala, Mater. Today: Proc., 2021, DOI: 10.1016/j.
matpr.2021.05.535, In press.
63 G. Metz, X. L. Wu and S. O. Smith, J. Magn. Reson., Ser. A,
1994, 110, 219–227.
64 B. M. Fung, A. K. Khitrin and K. Ermolaev, J. Magn. Reson.,
2000, 142, 97–101.
65 C. R. Morcombe and K. W. Zilm, J. Magn. Reson., 2003, 162,
479–486.
66 M. J. Potrzebowski, P. Tekely and Y. Dusausoy, Solid State
Nucl. Magn. Reson., 1998, 11, 253–257.
67 A. Bielecki and D. P. Burum, J. Magn. Reson., 1995, 116,
215–220.
68 X. Guan and R. E. Stark, Solid State Nucl. Magn. Reson.,
2010, 38, 74–76.
69 A. Vyalikh, P. Simon, E. Rosseeva, J. Buder, U. Scheler and R.
Kniep, Sci. Rep., 2015, 5, 15797.
70 P. Hohenberg and W. Kohn, Phys. Rev., 1964, 136, B864.
71 W. Kohn and L. J. Sham, Phys. Rev., 1965, 140, A1133–A1138.
72 M. C. Payne, M. P. Teter, D. C. Allan, T. A. Arias and J. D.
Joannopoulos, Rev. Mod. Phys., 1992, 64, 1045–1097.
73 C. J. Pickard and F. Mauri, Phys. Rev. B: Condens. Matter
Mater. Phys., 2001, 63, 245101.
74 S. J. Clark, M. D. Segall, C. J. Pickard, P. J. Hasnip, M. J.
Probert, K. Refson and M. C. Payne, Z. Kristallogr., 2005, 220,
567–570.
75 Dassault Systèmes BIOVIA, Materials Studio, version 17,
Dassault Systèmes, San Diego, 2017.
76 J. P. Perdew, K. Burke and M. Ernzerhof, Phys. Rev. Lett.,
1996, 77, 3865–3868.
77 A. Tkatchenko and M. Scheffler, Phys. Rev. Lett., 2009, 102,
073005.
78 N. Govind, M. Petersen, G. Fitzgerald, D. King-Smith and J.
Andzelm, Comput. Mater. Sci., 2003, 28, 250–258.
79 T. A. Halgren and W. N. Lipscomb, Chem. Phys. Lett.,
1977, 49, 225–232.
80 B. Delley, J. Chem. Phys., 1990, 92, 508–517.
81 B. Delley, J. Chem. Phys., 2000, 113, 7756–7764.
82 M. J. Turner, S. P. Thomas, M. W. Shi, D. Jayatilaka
and M. A. Spackman, Chem. Commun., 2015, 51,
3735–3738.
83 A. Gavezzotti, Z. Kristallogr., 2005, 220, 499–510.
84 H. Abouhakim, S. O. Nilsson Lill, M. J. Quayle, S. T. Norberg,
A. Hassanpour and C. M. Pask, Acta Crystallogr., Sect. B:
Struct. Sci., Cryst. Eng. Mater., 2020, 76, 275–284.
85 O. D. Putra, A. Pettersen, S. O. Nilsson Lill, D. Umeda, E.
Yonemochi, Y. P. Nugraha and H. Uekusa, CrystEngComm,
2019, 21, 2053–2057.
CrystEngCommPaper
O
pe
n 
A
cc
es
s 
A
rt
ic
le
. P
ub
lis
he
d 
on
 0
2 
Se
pt
em
be
r 
20
21
. D
ow
nl
oa
de
d 
on
 9
/1
4/
20
21
 4
:0
3:
54
 P
M
. 
 T
hi
s 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
C
om
m
on
s 
A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
L
ic
en
ce
.
View Article Online
